Need a Health professional?

Shreyaansh Lifesciences, Jaipur. India

Alectinib Capsules 150 mg
Alectinib Capsules is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Alectinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.

Alectinib Capsules was approved for medical use in the United States in 2015. It is on the World Health Organization’s List of Essential Medicines.

Alectinib Capsules Available Price In India UK Saudi Arabia

Alectinib Capsules

  • Innovator Brand Name – N/A
  • Generic Brand Available – Alecensa
  • API – Alectinib
  • Packaging – 240 Capsules
  • Strength – 150 mg

What is Alectinib Capsules used for?

 Alectinib Capsules is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Alectinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.

    Disclaimer

    All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

    Get Access To Alectinib Capsules 150 mg

    Shreyaansh Lifesciences, Jaipur. India

    Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act. 
    Branch Offices in India : Jaipur | New Delhi

    SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.

    +91 99292 77766

    Facts of Medicines

    Alectinib Capsules 150 mg

    INDICATIONS AND USAGE
    ALECENSA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung
    cancer (NSCLC) as detected by an FDA-approved test.

    DOSAGE AND ADMINISTRATION
    600 mg orally twice daily. Administer ALECENSA with food.

    ADVERSE REACTIONS
    The most common adverse reactions (incidence ≥20%) were fatigue, constipation, edema, myalgia, and anemia

    WARNINGS AND PRECAUTION
    • Hepatotoxicity: Monitor liver laboratory tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated,
    with more frequent testing in patients who develop transaminase and bilirubin elevations. In case of severe ALT, AST, or bilirubin elevations,
    withhold, then reduce dose, or permanently discontinue ALECENSA.
    • Interstitial Lung Disease (ILD)/Pneumonitis: Immediately withholdALECENSA in patients diagnosed with ILD/pneumonitis and permanently
    discontinue if no other potential causes of ILD/pneumonitis have been identified.
    • Renal Impairment: Withhold ALECENSA for severe renal impairment, then resume ALECENSA at reduced dose upon recovery or permanently discontinue
    • Bradycardia: Monitor heart rate and blood pressure regularly. If symptomatic, withhold ALECENSA then reduce dose, or permanently discontinue.
    • Severe Myalgia and Creatine Phosphokinase (CPK) Elevation: Assess CPK every 2 weeks during the first month of treatment and in patients reporting
    unexplained muscle pain, tenderness, or weakness. In case of severe CPK elevations, withhold, then resume or reduce dose.
    • Embryo-Fetal Toxicity: ALECENSA can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

    FAQs – Medicine Questions

    Alectinib Capsules 150 mg
    Is alectinib a chemotherapy?
    Alectinib is more effective than standard chemotherapy in patients with advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) who have progressed on—or are intolerant to—crizotinib, according to a recent study.
    What is alectinib used for?
    Alectinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body. Alectinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
    How long can you take alectinib?

    In the clinical trial ALEX: NCT02075840, the length of time Alecensa was taken ranged from months to over a year, with the median length of time being 18.6 months. Alecensa treatment usually continues until there is disease progression or the patient has unacceptable side effects
    Where can I buy Alectinib Capsules?

    You can buy Alectinib Capsules from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

    The buyer should check the existing law in their home country before importing the product.

    What is the procedure to buy Alectinib Capsules?

    Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020   We will reply ASAP with the details of the Alectinib Capsules price as well as procurement procedure.

    Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

    How is alectinib administered?

    The recommended dose of ALECENSA is 600 mg orally twice daily [see CLINICAL PHARMACOLOGY]. Administer ALECENSA until disease progression or unacceptable toxicity.

    NEWS / UPDATES

    1. Kuo et al., A retrospective study of Alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed, BMC Cancer, 2021, 21:309, [Accessed on 29th Mar 2021] https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08005-1
    2. Roche, Electronic Medicines Compendium (EMC), [Revised on Apr 2020] [Accessed on 29th Mar 2021] https://www.medicines.org.uk/emc/files/pil.2438.pdf
    3. Genentech, Inc., [Revised on Sep 2021] [Accessed on 27th Nov 2021], https://www.gene.com/download/pdf/alecensa_prescribing.pdf
    4. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.